Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells

Ann Oncol. 2016 Mar;27(3):546-7. doi: 10.1093/annonc/mdv580. Epub 2015 Nov 24.

Authors

S Kanameishi¹, A Otsuka², Y Nonomura¹, A Fujisawa¹, Y Endo¹, K Kabashima¹

Affiliations

¹ Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
² Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan otsukamn@kuhp.kyoto-u.ac.jp.

PMID: 26602778
DOI: 10.1093/annonc/mdv580

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
B-Lymphocytes / metabolism
Female
Humans
Immunoglobulins, Intravenous / therapeutic use
Lung Neoplasms / drug therapy
Lung Neoplasms / secondary
Melanoma / drug therapy
Melanoma / pathology
Nivolumab
Platelet Transfusion
Prednisolone / therapeutic use
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Programmed Cell Death 1 Receptor / metabolism
Purpura, Thrombocytopenic, Idiopathic / chemically induced*
Purpura, Thrombocytopenic, Idiopathic / therapy*
Receptors, Fc / therapeutic use
Recombinant Fusion Proteins / therapeutic use
Thrombopoietin / therapeutic use

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Immunoglobulins, Intravenous
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Receptors, Fc
Recombinant Fusion Proteins
Nivolumab
Thrombopoietin
Prednisolone
romiplostim